Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
Acute myeloid leukemia (AML) with BCR-ABL1 is rare and has a poor prognosis with conventional chemotherapy or ABL tyrosine kinase inhibitors (TKIs) alone. We reported a case of AML with BCR-ABL1 patient who was successfully treated with dasatinib alone; additionally, we previously reported another c...
Main Authors: | Asako Takeuchi, Toshinori Kondo, Taizo Tasaka, Seiko Yamada, Tadashi Hirose, Hirofumi Fukuda, Risa Shimizu, Yoshiko Matsuhashi, Eisei Kondo, Hideho Wada |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Leukemia Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S221304892030039X |
Similar Items
-
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
by: Mian Afsar, et al.
Published: (2012-09-01) -
Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
by: Khateb Mamduh, et al.
Published: (2012-11-01) -
Frequency of the minor BCR-ABL (e1;a2) transcript oncogene in a Mexican population with adult acute lymphoblastic leukaemia
by: I. Olarte-Carrillo, et al.
Published: (2015-07-01) -
Study of B3A2 fusion which is the most common mutation of ABL-BCR in chronic myeloid leukemia patients in Lorestan Province
by: Ali asghar Kiani, et al.
Published: (2016-12-01) -
Transcripto BCR-ABL atípico en un paciente con leucemia mieloide crónica Atypical BCR-ABL transcript in a patient with chronic myeloid leukemia
by: Ana María Amor Vigil, et al.
Published: (2011-09-01)